pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 0
- Drugs
- 34
- Patents
- 0
eptacog alfa (activated)
Phase 3 · small molecule · Acquired Bleeding Disorder
eptacog alfa (activated) for Acquired Bleeding Disorder is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code F7ICH-1641
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Acquired Bleeding Disorder
- Status
- completed
- Trials
- 1